Abstract Details
|
Scott R. Plotkin, MD, PhD, FAAN
(Mass General Cancer Center)
PRESENTER |
Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has stock in SonALAsense. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care. |
| No disclosure on file | |
| Nicole Ullrich, MD, PhD, MMSci, FAAN (Boston Children'S Hospital) | Dr. Ullrich has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion Pharmaceuticals. The institution of Dr. Ullrich has received research support from Children's Tumor Foundation. Dr. Ullrich has received intellectual property interests from a discovery or technology relating to health care. Dr. Ullrich has received publishing royalties from a publication relating to health care. |
| Jeffrey C. Allen, MD, FAAN (NYU Langone Medical Center) | No disclosure on file |
| Jaishri Blakeley, MD, FAAN (Johns Hopkins University School of Medicine) | Dr. Blakeley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Springworks Therapeutics. |
| Tena Rosser, MD (Childrens Hospital Los Angeles) | Dr. Rosser has received publishing royalties from a publication relating to health care. Dr. Rosser has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with Children's Tumor Foundation. Dr. Rosser has received personal compensation in the range of $500-$4,999 for serving as a Speaker/consultant with Springworks Therapeutics. |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Gary R. Cutter, PhD (University of Alabama At Birmingham) | Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biodelivery Sciences International, Biogen, Click Therapeutics, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein-Buendel Incorporated, Medimmune/Viela Bio, Medday, Merck/Serono, Neurogenesis LTD, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion/Cerexis Pharmaceuticals, Regeneron, Reckover Pharmaceuticals, Roche, TG Therapeutics.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Therapeutics, AI therapeutics, AMO Pharma, Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Green Valley Pharma, Horizon Pharmaceuticals, Immunic, Karuna Therapeutics, Mapi Pharmaceuticals LTD, Merck, Mitsubishi Tanabe Pharma Holdings, Opko Biologics,Prothena Biosciences, Novartis, Regeneron, Sanofi-Aventis, Reata Pharmaceuticals, NHLBI (Protocol Review Committee), University of Texas Southwestern, University of Pennsylvania, Visioneering Technologies, Inc.. Dr. Cutter has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN. |
| Bruce R. Korf, MD (University of Alabama At Birmingham) | Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SpringWorks Pharmaceuticals. Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Healx. Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Recursion. Dr. Korf has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genome Medical. Dr. Korf has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Infixion. Dr. Korf has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Journal of Human Genetics. Dr. Korf has stock in Genome Medical. The institution of Dr. Korf has received research support from NIH. The institution of Dr. Korf has received research support from Department of Defense. The institution of Dr. Korf has received research support from Children's Tumor Foundation. Dr. Korf has received publishing royalties from a publication relating to health care. Dr. Korf has received publishing royalties from a publication relating to health care. Dr. Korf has received publishing royalties from a publication relating to health care. |
| Roger J. Packer, MD (Children's National Medical Center, Neurology Dept) | No disclosure on file |
| No disclosure on file | |
| Matthias Karajannis | No disclosure on file |